Notícias

Wall Street ended lower as market participants weighed inflation concerns, rising oil prices and interest-rate expectations.

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with extensive-stage small-cell lung cancer.

Here are four highlights of a rocky day in markets Tuesday. Canadian tariffs on U.S. goods kicked in. Oil rose, while stocks fell. Amgen stock shed 10% Howmet Aerospace was the worst performer in the S&P.

Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.

📣 “This is the worst possible outcome for Amgen.” —Barclays analyst Emily Field, on Novartis announcing a disappointing result for its heart disease drug, a disclsoure that also cast doubt on one of Amgen's big drugs.

(Updates with index/price moves, macroeconomic data and company/geopolitical news from the first par

US equity indexes ended lower Tuesday after an Iran-backed militia group attacked Saudi Arabian ener

Disparate but related tensions among the U.S., Canada and Iran continue to roil financial markets.

(Updates with index/price moves and geopolitical news from the first paragraph.) US equity indexe

Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since October 2000. The decline came after Novartis announced a failure of its heart disease drug, pelacarsen, to reduce the risk of cardiovascular events compared with a placebo. The failure, which sent U.S.-traded Novartis shares down 14%, also cast doubt on similar drugs, including Amgen’s investigational treatment olpasiran.

Major stock indexes faced pressure on Tuesday with a fresh slate of geopolitical tensions weighing on investors. The Dow industrials are down about 1%. Meanwhile, quantum computing stocks are on the rise.

Amgen's (AMGN) experimental heart drug olpasiran may still show a meaningful reduction in major card

Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

The 563-patient study hit three efficacy endpoints, but investors still lack hazard ratios and regulatory timing.

3 biopharma stocks seeing high options volume

All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve

Amgen shares are following Novartis lower in the wake of disappointing clinical trial results.

The Dow lost 500 points early into Tuesday's trading session. Here's what's driving the loss. Most components in the blue chip index were in the red, but there was one name seeing the most dramatic downturn.

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.

Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death

Stock Market Today: The Dow Jones index declined 400 points Tuesday, as oil prices jumped on continued U.S.-Iran attacks.

Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.

Wall Street returns from summer vacation to a market suddenly bracing for a rate hike, with fresh analyst calls on Intel, Lockheed Martin, Amgen, and SpaceX adding more pressure points to an already tense week.

Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.

​Brent crude nears $100, Amgen stock falls, SpaceX lands $3 trillion valuation, and the latest on the Amazon plane crash.

Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.

AI stocks rise despite the market’s inflation worries, but Amgen falls following Swiss drugmaker Novartis’ disappointing trial data.

Amgen (NASDAQ:AMGN) shares fell 4. 7% to $416.

Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.